QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
NASDAQ:ISEE

IVERIC bio (ISEE) Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$39.95
$39.95
50-Day Range
$36.90
$39.95
52-Week Range
$9.39
$39.99
Volume
N/A
Average Volume
3.62 million shs
Market Capitalization
$5.50 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.75

ISEE vs. ZLAB, XENE, INSP, ELAN, ASND, BRBR, IMVT, ENSG, ABCM, and ITCI

Should you be buying IVERIC bio stock or one of its competitors? The main competitors of IVERIC bio include Zai Lab (ZLAB), Xenon Pharmaceuticals (XENE), Inspire Medical Systems (INSP), Elanco Animal Health (ELAN), Ascendis Pharma A/S (ASND), BellRing Brands (BRBR), Immunovant (IMVT), The Ensign Group (ENSG), Abcam (ABCM), and Intra-Cellular Therapies (ITCI). These companies are all part of the "medical" sector.

IVERIC bio vs.

Zai Lab (NASDAQ:ZLAB) and IVERIC bio (NASDAQ:ISEE) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, community ranking, dividends, media sentiment, risk, valuation and institutional ownership.

Zai Lab presently has a consensus price target of $83.10, suggesting a potential upside of 248.72%. IVERIC bio has a consensus price target of $25.75, suggesting a potential downside of 35.54%. Given IVERIC bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Zai Lab is more favorable than IVERIC bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zai Lab
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
IVERIC bio
0 Sell rating(s)
10 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

IVERIC bio has a net margin of 0.00% compared to IVERIC bio's net margin of -156.07%. IVERIC bio's return on equity of -38.48% beat Zai Lab's return on equity.

Company Net Margins Return on Equity Return on Assets
Zai Lab-156.07% -38.48% -32.78%
IVERIC bio N/A -57.00%-46.15%

Zai Lab has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Comparatively, IVERIC bio has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500.

IVERIC bio has lower revenue, but higher earnings than Zai Lab. IVERIC bio is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zai Lab$215.04M10.95-$443.29M-$4.09-5.83
IVERIC bioN/AN/A-$185.21M-$1.76-22.70

In the previous week, Zai Lab had 1 more articles in the media than IVERIC bio. MarketBeat recorded 1 mentions for Zai Lab and 0 mentions for IVERIC bio. IVERIC bio's average media sentiment score of 1.87 beat Zai Lab's score of 0.45 indicating that Zai Lab is being referred to more favorably in the media.

Company Overall Sentiment
Zai Lab Very Positive
IVERIC bio Neutral

Zai Lab received 153 more outperform votes than IVERIC bio when rated by MarketBeat users. Likewise, 62.50% of users gave Zai Lab an outperform vote while only 42.86% of users gave IVERIC bio an outperform vote.

CompanyUnderperformOutperform
Zai LabOutperform Votes
210
62.50%
Underperform Votes
126
37.50%
IVERIC bioOutperform Votes
57
42.86%
Underperform Votes
76
57.14%

43.7% of Zai Lab shares are held by institutional investors. 5.2% of Zai Lab shares are held by company insiders. Comparatively, 2.7% of IVERIC bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Zai Lab beats IVERIC bio on 14 of the 17 factors compared between the two stocks.


Get IVERIC bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for ISEE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ISEE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ISEE vs. The Competition

MetricIVERIC bioBiotechnology IndustryMedical SectorNASDAQ Exchange
Market Cap$5.50B$210.32M$4.29B$6.33B
Dividend YieldN/A2.93%5.94%7.81%
P/E Ratio-22.70292.81114.6612.37
Price / SalesN/A22,606.242,968.7853.38
Price / CashN/A11.5921.4122.76
Price / Book9.024.863.944.68
Net Income-$185.21M-$20.84M$121.41M$181.56M

IVERIC bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZLAB
Zai Lab
1.921 of 5 stars
$24.92
+0.4%
$83.10
+233.5%
-28.9%$2.46B$215.04M-6.092,036Gap Down
XENE
Xenon Pharmaceuticals
2.1624 of 5 stars
$35.03
-0.8%
$52.40
+49.6%
-5.4%$2.25B$9.43M-14.07203
INSP
Inspire Medical Systems
2.8416 of 5 stars
$187.31
+1.2%
$345.08
+84.2%
+11.9%$5.50B$407.86M-130.08755Analyst Report
Short Interest ↑
Positive News
ELAN
Elanco Animal Health
1.9123 of 5 stars
$11.35
+0.6%
$15.10
+33.0%
-9.4%$5.59B$4.42B-56.759,000
ASND
Ascendis Pharma A/S
2.0456 of 5 stars
$94.21
-1.4%
$145.20
+54.1%
-9.3%$5.38B$53.93M-8.34797Short Interest ↓
Positive News
BRBR
BellRing Brands
2.1539 of 5 stars
$40.54
-1.3%
$40.62
+0.2%
+100.0%$5.33B$1.37B35.56380Positive News
IMVT
Immunovant
1.5511 of 5 stars
$39.96
+97.0%
$30.00
-24.9%
+588.0%$5.22BN/A-20.70164Analyst Revision
High Trading Volume
ENSG
The Ensign Group
2.4813 of 5 stars
$92.74
-1.5%
$112.25
+21.0%
+16.9%$5.21B$3.39B21.9829,900Short Interest ↑
ABCM
Abcam
1.9094 of 5 stars
$22.67
-0.2%
$23.00
+1.5%
+51.0%$5.20B$447.49M0.001,760Short Interest ↓
Positive News
ITCI
Intra-Cellular Therapies
2.7252 of 5 stars
$53.75
-1.0%
$78.78
+46.6%
+11.9%$5.16B$250.31M-27.85561Short Interest ↓
Positive News

Related Companies and Tools

This page (NASDAQ:ISEE) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -